Table 3.
Demographic and clinical characteristics by latent class.
| Characteristic | All Low (1) n = 241 (61%) | Low Pain and High Fatigue (2) n = 124 (31.6%) | All High (3) n = 28 (7.1%) | Comparison Among 1,2, and 3 | Comparison Between 1 & 3 |
|---|---|---|---|---|---|
|
| |||||
| Mean (SD) | Statistic and p-value | ||||
| Age (years) | 56.9 (12.1) | 52.0 (9.4) | 50.7 (9.4) |
F(2,390) = 9.72, p < .0001 1 > 2 and 3 |
t = 2.60; p = .01 |
| Education (years) | 15.7 (2.7) | 16.0 (2.6) | 14.0 (2.6) |
F(2,385) = 6.5, p = .002 1 and 2 > 3 |
t = 3.18; p = .002 |
| Number biopsies in past year | 1.5 (0.7) | 1.5 (0.9) | 1.7 (1.1) | NS | NS |
| Karnofsky Performance Status score | 95.6 (8.2) | 90.4 (11.8) | 84.4 (12.5) |
F(2,284) = 23.0, p < .0001 1 > 2 >3 |
t = 4.53; p < .0001 |
| Self-administered Comorbidity Questionnaire score | 4.1 (2.7) | 4.5 (3.1) | 5.1 (2.7) | NS | t = - 2.00 ; p = .047 |
| Body mass index (kg/m2) | 26.5 (6.1) | 27.5 (6.2) | 26.9 (6.7) | NS | NS |
| % (N) | |||||
| Lives alone | 22.9 (55) | 23.0 (28) | 46.2 (12) | Χ2 = 7.08, p = .029 | FE; p = .016 |
| Married/partnered | 42.3 (102) | 38.2 (47) | 60.0 (15) | NS | NS |
| Ethnicity | Χ2 = 24.3, p = .<.0001 | X2 = 17.55; p = .001 | |||
| White | 65.4 (157) | 69.9 (86) | 32.1 (9) | ||
| Black | 8.8 (21) | 7.3 (9) | 28.6 (8) | ||
| Asian/Pacific Islander | 13.3 (32) | 8.1 (10) | 28.6 (8) | ||
| Hispanic/Mixed | 12.5 (30) | 14.6 (18) | 10.7 (3) | ||
| Income | Χ2 = 19.5, p = .001 | X2 = 17.89; p = < .0001 | |||
| < $30,000 | 17.7 (35) | 21.9 (23) | 57.1 (12) | ||
| $30,000–$99,000 | 43.9 (87) | 35.2 (37) | 28.6 (6) | ||
| ≥ $100,000 | 38.4 (76) | 42.9 (45) | 14.3 (3) | ||
| Stage of disease | NS | MW = .018 | |||
| Stage 0 | 19.9 (48) | 16.9 (21) | 14.3 (4) | ||
| Stage I | 38.2 (92) | 40.3 (50) | 21.4 (6) | ||
| Stage IIA and IIB | 35.3 (85) | 33.9 (42) | 42.9 (12) | ||
| Stage IIIA, IIIB, IIIC, and IV | 6.6 (16) | 8.9 (11) | 21.4 (6) | ||
| Estrogen receptor positive | 82.1 (197) | 69.4 (86) | 67.9 (19) | Χ2 = 8.9, p = .012 | NS |
| Progesterone receptor positive | 75.4 (181) | 61.3 (76) | 64.3 (18) | Χ2 = 8.3, p = .016 | NS |
| HER2/neu receptor positive | 13.1 (28) | 21.9 (25) | 18.5 (5) | NS | NS |
| Gone through menopause | 65.8 (158) | 60.2 (118) | 64.0 (16) | NS | NS |
| Received neoadjuvant therapy | 16.3 (39) | 27.4 (34) | 21.4 (6) | Χ2 = 6.4, p = .041 | NS |
| Received hormone replacement therapy prior to cancer diagnosis | 17.5 (42) | 17.1 (21) | 10.7 (3) | NS | NS |
Note. FE = Fisher’s exact test; HER2 = human epidermal growth factor receptor 2; MW = Mann Whitney U; NS = not significant; SD = standard deviation.